HIF-1α siRNA Enhances the Efficacy of Erlotinib in Non-small Cell Lung Cancer: A Novel Strategy to Reverse Hypoxia-Induced Drug Resistance

Key Points

• The aim is to investigate how targeting HIF-1α can improve the effectiveness of erlotinib in overcoming drug resistance in non-small cell lung cancer.
• Examined the impact of HIF-1α siRNA on erlotinib efficacy
• Focused on non-small cell lung cancer models
• Analyzed metabolic reprogramming and hypoxia adaptation pathways
• HIF-1α inhibition significantly enhanced erlotinib's effectiveness
• The approach showed promise in reversing drug resistance
• Combined treatment disrupted hypoxia-related metabolic changes